利妥昔单抗治疗乙酰胆碱受体抗体阳性全身型重症肌无力的2期试验:BeatMG研究
BeatMG是一项随机、双盲、安慰剂对照、多中心2期试验,采用无效性设计,纳入52例接受泼尼松≥15 mg/天的乙酰胆碱受体抗体阳性全身型重症肌无力患者,评估利妥昔单抗减少激素用量和安全性的效果。结果显示,利妥昔单抗组60% vs 安慰剂组56%达到主要激素减量终点,研究达到无效性终点(p=0.03),提示在后续更大规模试验中不太可能实现预设的30%临床意义改善。利妥昔单抗安全且耐受性良好,但12个月内减少激素使用的可能性低。
要点
- 利妥昔单抗在乙酰胆碱受体抗体阳性全身型重症肌无力中安全且耐受性良好。
- 主要终点激素减量率利妥昔单抗组60% vs 安慰剂组56%,研究达到无效性终点(p=0.03)。
- 结果提示在3期试验中观察到达30%临床意义激素减量效果的概率低。
核心结论
- 利妥昔单抗安全且耐受性良好,但结果提示在12个月内轻度至中度症状的乙酰胆碱受体抗体阳性全身型重症肌无力患者中,观察到预设临床意义激素减量效果的概率低。
研究设计与样本
- B细胞靶向治疗重症肌无力(BeatMG)研究是一项随机、双盲、安慰剂对照、多中心2期试验,采用无效性设计。
- 纳入21-90岁、乙酰胆碱受体抗体阳性全身型重症肌无力(美国重症肌无力基金会II-IV级)且接受泼尼松≥15 mg/天的个体。
- 52例个体按1:1随机分配至两周期利妥昔单抗/安慰剂方案,随访至52周。
- 主要结局为激素节省效果,定义为在52周前4周内平均每日泼尼松剂量较随机化前4周期间减少≥75%且临床改善或无显著恶化。
- 共同主要结局为安全性。
主要发现
- 52例参与者中,入组时平均(±SD)年龄为55.1(±17.1)岁;23例(44.2%)为女性,31例(59.6%)为MGFA II级。
- 平均(±SD)基线泼尼松剂量为22.1(±9.7)mg/天。
- 主要激素节省结局在利妥昔单抗组60% vs 安慰剂组56%达到。
- 研究达到无效性终点(p=0.03),提示利妥昔单抗相比安慰剂预设的30%临床意义改善在后续更大规模试验中不太可能实现。
- 未发现安全性问题。
关键数值与推荐
- 主要激素节省结局:利妥昔单抗组60% vs 安慰剂组56%。
- 无效性终点p=0.03。
- 预设临床意义改善为利妥昔单抗相比安慰剂绝对差异至少30%。
临床怎么用
- 作者认为,对于轻度至中度症状的乙酰胆碱受体抗体阳性全身型重症肌无力,与安慰剂相比,利妥昔单抗安全但不太可能在1年内减少激素使用达至少30%的绝对差异。
局限性
- 研究达到无效性终点(p=0.03),提示预设的30%临床意义改善在后续更大规模试验中不太可能实现。
- 结果提示在12个月内观察到预设临床意义激素减量效果的概率低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether rituximab is safe and potentially beneficial, warranting further investigation in an efficacy trial for acetylcholine receptor antibody-positive generalized MG (AChR-Ab+ gMG). METHODS: The B-Cell Targeted Treatment in MG (BeatMG) study was a randomized, double-blind, placebo-controlled, multicenter phase-2 trial that utilized a futility design. Individuals 21-90 years of age, with AChR-Ab+ gMG (MG Foundation of America Class II-IV) and receiving prednisone ≥15 mg/day were eligible. The primary outcome was a measure of steroid-sparing effect, defined as the proportion achieving ≥75% reduction in mean daily prednisone dose in the 4-weeks prior to week 52 and with clinical improvement or no significant worsening as compared to the 4-week period prior to randomization. The co-primary outcome was safety. Secondary outcomes included MG-specific clinical assessments. Fifty-two individuals were randomized (1:1) to either a two-cycle rituximab/placebo regimen, with follow-up through 52-weeks. RESULTS: Of the 52 participants included, mean (±SD) age at enrollment was 55.1 (±17.1) years; 23 (44.2%) were female, and 31 (59.6%) were MGFA Class II. The mean (±SD) baseline prednisone dose was 22.1 (±9.7) mg/day. The primary steroid-sparing outcome was achieved in 60% of those on rituximab vs. 56% on placebo. The study reached its futility endpoint (p=0.03) suggesting that the pre-defined clinically meaningful improvement of 30% due to rituximab over placebo was unlikely to be achieved in a subsequent, larger trial. No safety issues identified. CONCLUSIONS: While rituximab was safe and well-tolerated, these results suggest that there is a low probability of observing the defined clinically meaningful steroid-sparing effect over a 12-month period in a phase-3 trial of mild-moderately symptomatic AChR-Ab+ gMG. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for mild-to-moderate AChR-Ab+ gMG, compared with placebo, rituximab is safe but unlikely to reduce steroid use by an absolute difference of at least 30% at 1 year. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02110706.
引用
- Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology. 2022. PMID: 34857535. doi:10.1212/WNL.0000000000013121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。